Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research report released on Monday. The firm issued a sell rating on the stock.

Oragenics Price Performance

Shares of NYSE:OGEN opened at $0.31 on Monday. The company has a market capitalization of $1.74 million, a P/E ratio of -0.04 and a beta of 0.49. Oragenics has a 1-year low of $0.28 and a 1-year high of $7.74. The firm’s 50 day simple moving average is $0.46 and its two-hundred day simple moving average is $1.06.

Oragenics (NYSE:OGEN) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.51) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new position in Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent SEC filing. 18.71% of the stock is owned by institutional investors and hedge funds.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.